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DOI 10.1016/j.stem.2011.08.013SUMMARY pathic patients with DCM and in familial DCM, suggests defectsCardiomyocyte remodeling, which includes partial
dedifferentiation of cardiomyocytes, is a process
that occurs during both acute and chronic disease
processes. Here, we demonstrate that oncostatin M
(OSM) is amajor mediator of cardiomyocyte dediffer-
entiation and remodeling during acute myocardial
infarction (MI) and in chronic dilated cardiomyopathy
(DCM). Patients suffering from DCM show a strong
and lasting increase of OSM expression and signal-
ing. OSM treatment induces dedifferentiation of car-
diomyocytes and upregulation of stem cell markers
and improves cardiac function after MI. Conversely,
inhibition of OSM signaling suppresses cardiomyo-
cyte remodeling after MI and in a mouse model of
DCM, resulting in deterioration of heart function
after MI but improvement of cardiac performance in
DCM. We postulate that dedifferentiation of cardio-
myocytes initially protects stressed hearts but fails
to support cardiac structure and function upon
continued activation. Manipulation of OSM signaling
provides a means to control the differentiation state
of cardiomyocytes and cellular plasticity.
INTRODUCTION
Heart failure is the functional consequence of an unresolved
impairment of the heart that compromises its ability to work as
a pump. The source of this can be, among others, an insufficient
blood supply, an increase in workload due to high blood pres-
sure or nonfunctioning valves, infections with cardiotropic
viruses, or genetic predisposition (Apostolakis et al., 2010).
Dilated cardiomyopathy (DCM) is a relatively common but poorly
understood group of heart muscle disorders leading to heart
failure. The majority of DCM cases have been linked to ischemic,
toxic, metabolic, or infectious causes and, in the absence of an
obvious etiological factor, are classified as ‘‘idiopathic.’’ The
reduced contractility, which is found in both sporadic and idio-420 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Incin transmission of contractile force as one mechanism for
ventricular dilation and dysfunction. In addition, loss of sarco-
mere organization and degeneration of cardiomyocytes has
been documented in patients with DCM during transition to
heart failure (Hein et al., 2009). The extensive heterogeneity of
the disease has been linked to yet unknown modifier genes
that might promote disorganization of sarcomers in cardiomyo-
cytes or to environmental factors such as cardiotropic viruses,
whichmight cause direct cytopathic effects or adverse reactions
of the host tissue, resulting in accumulation of macrophages
in the myocardium of patients with DCM (Shioi et al., 1996).
The process of inflammatory cellular infiltration is not only
restricted to DCM, but is also well described in ischemic heart
disease and other cardiac disorders. In all cases infiltrating
macrophages contribute to cytokine production (Apostolakis
et al., 2010), which might favor disorganization of sarcomers in
cardiomyocytes.
Changes of the sarcomeric structure of cardiomyocytes under
pathological conditions characterized by the disappearance
of the highly organized patterns of myosins, titin, and desmin
sometimes generate a state resembling the phenotype of
embryonic and fetal cardiomyocytes (Driesen et al., 2009).
Such dedifferentiated cardiomyocytes can be found in infarction
border zones (BZs) (Dispersyn et al., 2002; Sharov et al., 1997),
volume-overloaded myocardium, and fibrillating atria (Ru¨cker-
Martin et al., 2002). The assumed negative consequences of
cardiomyocyte dedifferentiation contrast with dedifferentiation/
redifferentiation-based regenerative circuits that have been
considered as an alternative mechanism to stem-cell-based
pathways to achieve tissue repair. In fact, some organisms,
such as zebrafish (Jopling et al., 2010) and amphibian newts
(Laube et al., 2006), seem to rely predominantly on the prolifera-
tion of dedifferentiated cardiomyocytes, which redifferentiate
after a phase of proliferation to regain a fully functional state.
Interestingly, cardiomyocytes in the hibernating myocardium,
which was originally described as a protective mechanism of
the heart that downregulates its function to cope with oxygen
shortage, show a dedifferentiated phenotype with structural hall-
marks of fetal heart cells (Dispersyn et al., 2002). The dedifferen-
tiated state might enable cardiomyocytes to survive under
unfavorable circumstances (Ausma et al., 1998). It also seems.
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OSM and Cardiomyocyte Dedifferentiationpossible that dedifferentiated cardiomyocytes give rise to
cardiac progenitor cells that contribute to the regeneration of
the heart, although evidence for such a hypothesis is limited to
in vitro studies so far (Zhang et al., 2010). Surprisingly little is
known about the signals that might induce dedifferentiation, in
particular in the heart. We have screened for signals that might
induce dedifferentiation and remodeling of cardiomyocytes
using tissue samples from patients suffering from DCM, which
is characterized by accumulation of large numbers of dedifferen-
tiated cardiomyocytes.
We discovered a consistent upregulation of oncostatin M
(OSM) in human patients and in a transgenic mouse model of
DCM. OSM is an inflammatory cytokine that belongs to the inter-
leukin-6 (IL-6) class of cytokines. It exertsmultiple functions such
as induction of dedifferentiation of adipocytes (Song et al., 2007)
and maintenance of erythroid and megakaryocyte progenitor
pools (Tanaka et al., 2003). In the heart, members of this family
have so far been mostly associated with cardiac hypertrophy
and cardiomyocyte survival due to activation of the common
coreceptor gp130 (Hirota et al., 1999), although OSM also
induces SDF1 and VEGF in cardiomyocytes and modulates
extracellular matrix degradation (Hohensinner et al., 2009; Weiss
et al., 2003, 2005). The focus on gp130-dependent signaling
distracted attention from important differences in signaling of
individual IL-6 cytokine family members, which utilize different
receptors. Only IL-6 and IL-11 induce homodimerization of
gp130, whereas OSM, LIF, and CT-1 induce heterodimerization
of gp130 with the OSM receptor (Ob) or LIF receptor (LIFR),
respectively (reviewed by Heinrich et al., 2003). To this point,
no efforts have been made to investigate the consequences of
Ob inactivation in the heart.
We found that OSM is positively correlated with dedifferentia-
tion of cardiomyocytes in both chronic (i.e., DCM) and acute
disease conditions (i.e., myocardial infarction [MI]). Functional
studies revealed that OSM is sufficient to induce dedifferentia-
tion of cardiomyocytes in vitro and in vivo. Our data reveal that
partial dedifferentiation of cardiomyocytes via OSM initially
protects the damaged myocardium but exerts adverse effects,
promoting heart failure in a chronic phase characterized by pro-
longed induction of dedifferentiation.
RESULTS
Increased Expression of OSM and Ob in Patients
Suffering from DCM and Acute MI
To identify components of signaling pathways that might lead
to dedifferentiation of cardiomyocytes and therefore favor
acquisition of a dilated phenotype, we investigated samples
of patients at different NYHA stages suffering from DCM
using a combination of 2D gel electrophoresis coupled to mass
spectrometry, Bio-Plex Multiplex cytokine assays, and high-
throughput western blotting (Table S1 available online and data
not shown). A strong expression of OSM and Ob (Figures 1A
and 1B) was detected in all patients examined but not in
healthy control samples. Confocal microscopy using an antibody
against CD68 revealed increased numbers of macrophages in
the interstitial space of DCM patients compared with control
myocardium, which explains the significant increase of OSM
and Ob in these patients (Figure S1A available online).CelWe next wanted to know whether accumulation of macro-
phages and increased expression of OSM and Ob correlated
with dedifferentiation of cardiomyocytes as indicated by activa-
tion of fetal heart genes and remodeling of cardiomyocytes
in DCM patients. Activation of fetal genes occurs in response
to biomechanical stress and is regarded as one of the earliest
and most consistent markers of cardiac remodeling (Izumo
et al., 1988). We detected expression of typical fetal genes
such as a-smoothmuscle actin (a-SM-actin) and atrial natriuretic
peptide (ANP) by western blot analysis (Figures 1A and 1B).
Immunofluorescence staining of heart specimens from DCM
patients also revealed a strong upregulation of a-smooth muscle
actinin (SM-actinin) in cardiomyocytes where it was found in
a cross-striated pattern and in intercalated discs (Figure 1C).
Staining for ANP was used as a positive control to reveal cardiac
remodeling in DCM patients (Figure S1B). Most smooth muscle
genes are expressed in embryonic cardiomyocytes at early
stages of heart development but are downregulated later during
development when cardiomyocytes differentiate fully (Boettger
et al., 2009). In healthy human control samples, expression of
SM-actinin was absent in cardiomyocytes and was confined
solely to vascular smooth muscle cells (Figure 1C).
Macrophage infiltration is not restricted to chronic disease
conditions such as DCM and also occurs during the course of
MI. We therefore examined expression of SM-actinin as an indi-
cator of cardiomyocyte dedifferentiation in samples from human
patients who experienced MI. Interestingly, SM-actinin was
strongly re-expressed in remaining cardiomyocytes within the
BZ of infarcted areas (Figure 1C). SM-actinin expression corre-
lated with the expression of OSM in the BZ (Figure S1E), which
has been described before in a canine model of ischemia/reper-
fusion injury (Gwechenberger et al., 2004). We also analyzed
expression of the actin depolymerizing protein destrin (Figures
1A and 1B), which was found in the perinuclear region and the
area of the intercalated discs of cardiomyocytes in all samples
derived from DCM patients, but was absent in normal human
myocardium (Figure S1C). Destrin was also strongly upregulated
in the perinuclear region of cardiomyocytes in the BZ of patients
with MIs (Figure S1D). Furthermore, we found a strong induction
of the stem cell marker Runx1 in nuclei of cardiomyocytes
located in the infarct BZ, but not in intact myocardium (Figure 1D)
(see below for the identification of Runx1 as the dedifferentiation
marker of cardiomyocytes).
OSM Induces Cardiomyocyte Dedifferentiation and
Activation of Fetal Genes In Vitro and Exerts Its Effects
via Ob by Stimulation of the Ras/Raf/MEK/Erk Cascade
The correlation of increased OSM signaling, cardiomyocyte
dedifferentiation, and activation of fetal genes in hearts of DCM
patients suggested a decisive role of OSM in these events. To
prove that dedifferentiation and remodeling of cardiomyocytes
was initiated by OSM and not by other molecules, we isolated
cardiomyocytes from adult rat hearts and treated them with
different cytokines and growth factors. OSM caused a marked
increase in cell size (Figures 2A and 2B, Figure S2A) and loss
of sarcomeric structures (a.k.a, dedifferentiation) (Figure 2A).
Striking morphological changes in individual cardiomyocytes
were detected by time-lapse imaging as soon as 3 days after
exposure to OSM. After 6 days, virtually all cardiomyocytesl Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Inc. 421
Figure 1. Increased Levels of OSM and Ob Expression Correlate with Activation of Fetal Gene Markers in Human Patients Suffering from
Dilated Cardiomyopathy
(A) Western blot analysis of the expression of oncostatin M (OSM), OSM receptor b (Ob), the 95 kDa B-Raf isoform, a-smooth muscle actin (a-SM-actin), destrin,
ANP, and Runx1. Statistical analysis is shown in (B). (C) Immunofluorescence analysis of SM-actinin expression. SM-actinin shows a cross-striated pattern and is
also localized at intercalated discs (white arrows). Staining of SM-actinin in smooth muscle cells of an artery in healthy controls is indicated by a ‘‘V’’ (for vessel).
(D) Immunofluorescence analysis of Runx1 expression. Multiple cardiomyocytes within the border zone of patients with myocardial infarction (BZ) show
expression of Runx1 whereas no expression in cardiomyocytes is seen in healthy control myocardium (con). The white arrows indicate cardiomyocyte nuclei and
the magnified portion of the image shows nuclear localization of Runx1. Error bars represent standard errors. Scale bars in (C) and (D): 30 mm. See also Figure S1
and Table S1.
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OSM and Cardiomyocyte Dedifferentiationacquired a dedifferentiated phenotype (Movie S1 available
online). Furthermore, we found re-expression of SM-actinin
(Figures 2B and 2C) and a-SM-actin (Figure 2D, Figure S2B),422 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Incand enhanced secretion of ANP (Figure S3A). Cardiomyocytes
retained low-level expression of myomesin and sarcomeric acti-
nin upon OSM treatment despite the massive loss of sarcomeric.
Figure 2. OSM Induces Cardiomyocyte
Dedifferentiation In Vitro by Stimulation of
the Ras/Raf/MEK/Erk Cascade via Ob
(A) Immunofluorescence analysis of a-SM-actin
(red) and myomesin (green) expression in car-
diomyocytes cultured with 2% serum plus IGF-1
or OSM for 10 days.
(B) Immunofluorescence analysis reveals the
presence of SM-actinin (red) in sarcomeric actinin
(green) -positive cardiomyocytes after 12 days of
OSM treatment. Scale bars: 30 mm.
(C and D) Western blot analysis of Ob (siOb)
knockdown in cardiomyocytes. Knockdown of Ob
prevents activation of Erk1/2 and fetal gene acti-
vation after OSM treatment.
Error bars represent standard errors. See also
Figure S2, Table S2, and Movie S1.
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OSM and Cardiomyocyte Dedifferentiationstructures and upregulation of SM-actinin and a-SM-actin, indi-
cating that dedifferentiation was not complete (Figure 2A, Fig-
ure S2B). The effect was most striking for OSM and only
occurred to a minor extent in response to other cytokines and
growth factors such as LIF, IL-6, cardiotrophin-1, insulin growth
factors (IGFs), interleukins, TNFs, MCPs, TGF-bs, BMPs, GDFs,
FGFs, Activin, angiotensin, and endothelin (Figures S2A and S3B
and data not shown). The dedifferentiation effects of OSM
contrast to the induction of new sarcomeres in cardiomyocytes
described for CT-1 and LIF (Kodama et al., 1997). IGF-1, a
well-known stimulator of sarcomerogenesis, served as positive
control, causing hypertrophy (Figure 2A).
To delineate the signaling pathways that might mediate
OSM signaling, we screened a large panel of phospho-specific
antibodies (>200) by high-throughput western blotting after stim-
ulation of adult rat cardiomyocytes with OSM (Table S2). We
detected a marked increase of Erk1/2 phosphorylation together
with a strong upregulation of the 95 kDa B-Raf (Figure 2D, Fig-
ure S2D). In addition, we observed enhanced phosphorylationCell Stem Cell 9, 420–432,of JAK1, STAT1, and STAT3, and of the
adaptor proteins Gab1 and Gab2. Next,
we wanted to know which OSM-stimu-
lated signal transduction pathway was
instrumental for induction of cardiomyo-
cyte dedifferentiation and remodeling
and activation of fetal genes. Concomi-
tant treatment of adult rat cardiomyo-
cytes with OSM and a battery (>50) of
small molecule inhibitors directed against
PI3K, p38, SAPK/JNK, and other signal-
ing molecules revealed a striking effect
of the MEK1/2 inhibitor UO126, which
efficiently blocked Erk1/2 activation in
cardiomyocytes (Figure 2D). UO126
completely abolished OSM-induced car-
diomyocyte elongation (Figure S2A) and
loss of sarcomeric structures (not
shown). Moreover, we observed a strong
inhibition of fetal gene marker activation
by UO126 as indicated by suppression
of re-expression of SM-actinin (Fig-ure 2C), a-SM actin, 95 kDa B-Raf, and destrin (Figure 2D),
and secretion of ANP (Figure S3A). Similar results were obtained
with siRNAs targeting Erk1/2 (Figure 2C). These results clearly
indicate that major effects of OSM were transmitted via the
Ras/Raf/MEK/Erk cascade. B-Raf seems to play a dual role as
both a marker of fetal gene expression and a component of the
Raf-signaling module together with C-Raf (data not shown).
OSM elicits its effects either via the type I receptor, which is
a heteromer of the gp130 and LIFR, or the type II receptor
complex, which consists of gp130 and the Ob. The type I
receptor binds both LIF and OSM while the type II receptor is
exclusively used by OSM. Since activation of fetal genes and
cardiomyocyte remodeling was mainly initiated by OSM, we
concluded that effects of OSM were mediated exclusively by
the type II receptor. To prove this hypothesis we used siRNAs
directed against Ob. Treatment of cardiomyocytes with Ob
siRNA inhibited OSM-induced upregulation of Ob and com-
pletely suppressed phosphorylation of the coreceptor gp130,
but did not affect other receptors such as TGF-bR1 (Figure S2C).November 4, 2011 ª2011 Elsevier Inc. 423
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OSM and Cardiomyocyte DedifferentiationWe found that knockdown of Ob in cardiomyocytes completely
abolished OSM-mediated phosphorylation of Erk1/2 and upre-
gulation of 95 kDa B-Raf (Figure S2D). Knockdown of Ob also
prevented induction of fetal gene marker expression and cardio-
myocyte dedifferentiation and remodeling, as indicated by
decreased expression of SM-actinin (Figure 2C), a-SM-actin,
destrin (Figures S2D), and ANP secretion (Figure S3A). The
degree of inhibition of dedifferentiation was similar to the effects
of the MEK1/2 inhibitor UO126 and also inhibited cell growth
(Figure S2B).
OSM-Mediated Dedifferentiation of Cardiomyocytes
Induces Expression of Progenitor Cell Markers
and Enables Cell-Cycle Progression
Because OSM-treated adult cardiomyocytes underwent
a pronounced dedifferentiation characterized by loss of sarco-
meric structures and started to express several markers typical
for fetal or embryonic cells, we investigated whether dedifferen-
tiated cardiomyocytes might also express progenitor cell
markers and acquire other properties of cardiac progenitor cells
or embryonic cardiomyocytes such as cell-cycle progression.
We compared transcriptional profiles obtained by Affymetrix
DNAmicroarray analysis from ESCs subjected to cardiomyocyte
differentiation to cardiomyocytes treated with OSM and selected
those genes that were significantly downregulated in differenti-
ating ESCs and significantly upregulated in OSM-treated cardio-
myocytes. These criteria defined a list of genes that included
several typical progenitor cell markers including c-kit (Beltrami
et al., 2003), Runx1 (Osorio et al., 2011), and Dab2 (Tumbar
et al., 2004). Validation of DNA microarray data by real-time
quantitative RT-PCR analysis revealed a 25-fold upregulation
of c-kit, a 15-fold upregulation of Runx1, and a 9-fold upregula-
tion ofDab2 in OSM-treated cardiomyocytes. a-SM-actin, which
was used a positive control of dedifferentiated cardiomyocytes,
showed a 6.9-fold upregulation (Figure 3A). In ESCs that were
differentiating to cardiomyocytes, these markers were downre-
gulated 1.5-fold (c-kit), 9-fold (Runx1), and 8.1-fold (Dab2).
Immunofluorescence staining of OSM-treated cardiomyocytes
indicated the presence of the transcription factor Runx1 in virtu-
ally all nuclei of OSM-treated cardiomyocytes, whereas Runx1
was absent in control cardiomyocytes (Figure 3B). Western blot
analysis confirmed the OSM-dependent upregulation of Runx1
in cardiomyocytes,whereasLIFwas far lesspotent in this respect
(Figure 3C). Inhibition of Erk signaling by UO126 completely
blunted Runx1 upregulation. Similar results were obtained for
Dab2 (Figure 3C). Due to their robust expression profile, we em-
ployed Runx1 and Dab2 as additional new markers for cardio-
myocyte dedifferentiation in the further course of this study.
We also wanted to know whether OSM-induced dedifferenti-
ation of cardiomyocytes enhances cell-cycle progression.
Therefore, neonatal cardiomyocytes were treated for 6 days
with OSM and subsequently exposed to FGF-2 or subjected
to infection with an E2F2 adenovirus, which induces S-phase
entry andmitosis in cardiomyocytes (Ebelt et al., 2005). Pretreat-
ment with OSM increased FGF-2- and E2F2-induced S-phase
entry, as measured by EdU incorporation (Figure 3D, Fig-
ure S3C), compared with FGF-2 or E2F2 treatment alone. Cardi-
omyocytes exposed to OSM alone also showed increased EdU
incorporation compared with untreated controls, which was424 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Incprobably due to the presence of fetal calf serum in the cultures
(Figure 3D).
OSM Is Required for Initiation of Cardiomyocyte
Dedifferentiation and Remodeling In Vivo
The strong induction of cardiomyocyte remodeling, expression
of progenitor cell markers, and dedifferentiation by OSM in vitro
raised the question of whether OSM is sufficient to cause similar
changes in vivo. Therefore, we treated 6-month-old mice twice
daily with 60 ng OSM per gram of body weight. After 14 days of
treatment, we observed expression of the progenitor cell marker
Runx1 in nuclei of cardiomyocytes (Figure 4A), increased ex-
pression of Dab2 (Figure 4B), and a significant increase of Ob
expression (Figure 4B). Likewise, the phosphorylation level of
gp130 at serine 782 (Figure 4B), which is the major site for
gp130phosphorylation (Gibson et al., 2000),was enhancedwhile
the expression of other members of the IL-6 family such as LIF
was unaffected (Figure S4B). Activation of the OSM signaling
cascade was also confirmed by enhanced phosphorylation of
Erk1/2 (Figure 4B) and upregulation of the 95 kDa B-Raf isoform
(Figure 4B). Moreover, we detected a marked re-expression of
SM-actinin (Figure 4B), SM-actin (Figure S4B), destrin (Fig-
ure S4B), and ANP (Figure 4A) in the myocardium. Immunostain-
ing also revealed the presence of SM-actin (Figure S4A) and SM-
actinin (Figure 4A) in cardiomyocytes after OSM injection, while
expression in the normal mouse myocardium was restricted to
vessels (FigureS4A).Moreover,OSMtreatment causedaccumu-
lation of destrin in the intercalated discs, indicating reorganiza-
tion of cardiomyocytes (Figure S4).
The ability of OSM to induce cardiomyocyte dedifferentiation
and expression of progenitor cell markers in vitro and in vivo
does not necessarily prove that OSM is necessary for induction
of cardiomyocyte dedifferentiation and activation of fetal gene
markers under pathological conditions. To address this problem
we took advantage of two different mouse models of cardiac
disease. The first model is based on the heart-specific overex-
pression of monocyte chemotactic protein-1 (MyHC-MCP-1,
MCP-1),which leads to infiltrationof themyocardiumwithmacro-
phages. Thepresenceofmacrophages results in chronicdamage
to the myocardium, which at the age of 6 months causes ventric-
ular dilatation and heart failure, thereby recapitulating major
features of human DCM (Kolattukudy et al., 1998). Hearts of 6-
month-oldMCP-1mice showed increased expression of Ob (Fig-
ure 5A), increased expression of OSM (Figure 5A), and increased
amounts of 95 kDaB-Raf (Figure 5B), ANP (Figure 5B), Dab2, and
Runx1 (Figure 5B), which essentially reiterates our findings in
human DCM patients. Moreover, we observed a strong re-
expression of SM-actinin (Figure 5C), ANP (Figure 5C), and des-
trin (Figure S4A) in cardiomyocytes of MCP-1 transgenic mice,
which is indicative of cardiomyocyte dedifferentiation.
Importantly, abrogation of OSM signaling in 6-month-old
animals by crossing Ob KO mice with the MCP-1 transgenic
strain blocked dedifferentiation of cardiomyocytes (Figures
5B and 5C) and resulted in major improvements of biochemical
and morphological parameters. Levels of B-Raf, ANP, Dab2,
and Runx1 returned to WT levels (Figure 5B), and SM-actinin
became restricted to vascular smooth muscle cells as in WT
animals, leaving cardiomyocytes devoid of SM-actinin staining
(Figure 5C)..
Figure 3. OSM Induces Dedifferentiation and DNA Synthesis in Cardiomyocytes In Vitro
(A) RT-PCR analysis of c-kit, Runx1, Dab2, SM-actin, and sarcomeric actinin expression in OSM-treated cardiomyocytes relative to untreated controls and in
differentiated cardiac bodies (CB) relative to undifferentiated embryoid bodies (EB). Bars represent fold-changes (*p < 0.05,Ap < 0.05).
(B) Fluorescent immunostaining of Runx1 expression (red) in nuclei (blue) of cardiomyocytes (green) after 10 days of OSM treatment but not in untreated controls.
(C)Western blot analysis of Dab2 andRunx1 expression in cardiomyocytes treated for 7 dayswith OSM. Addition of UO126 (UO) prevents expression of Dab2 and
Runx1.
(D) Statistical analysis of EdU incorporation in neonatal cardiomyocytes cultured in the presence of OSM for 6 days followed by treatment with FGF-2 (OSM + F2)
or Ad-E2F2 (OSM + E2F2) for 2 days. Cardiomyocytes without OSM treatment but with FGF-2 (F2) or Ad-E2F2 (E2F2) from day 6 to day 8 served as controls.
Error bars represent standard errors. See also Figure S3.
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OSM and Cardiomyocyte DedifferentiationThe second model exploited acute myocardial damage
caused by ligation of the left anterior descending coronary artery
(LAD) at a distal position. This intervention causes antero-apical
myocardial scars with a comparatively small lethality. MI induces
massive recruitment of macrophages to infarcted areas (Fig-
ure 6A), but this accumulation occurs only transiently. We foundCelthat macrophages in the infarcted area and in the neighboring BZ
expressed high levels of OSM (Figure 6A). A striking re-expres-
sion of SM-actinin was observed in cardiomyocytes located in
the infarct BZ of operated animals (Figure 6B), which indicates
dedifferentiation of cardiomyocytes and recapitulates our find-
ings in human patients (Figure 1C). Furthermore, we detectedl Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Inc. 425
Figure 4. OSM Is Sufficient to Induce Fetal Gene Markers In Vivo
(A) Immunofluorescence and (B) western blot analysis of themyocardium of OSM-treated 6-month-oldWTmice. Treatment ofmicewith OSM for 14 days induces
expression of fetal gene markers and remodeling in the myocardium. Error bars represent standard errors. (A) OSM-induced expression of Runx1 (red) in
cardiomyocytes (green) (scale bars: 40 mm), as well as ANP (green) and SM-actinin (green) in cardiomyocytes (red) (scale bars: 30 mm), compared with mock
treated controls (con). Staining of SM-actinin in smooth muscle cells of an artery is indicated by ‘‘V’’ (for vessel). See also Figure S4.
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OSM and Cardiomyocyte Dedifferentiationstrong expression of the progenitor cell marker Runx1 in large
numbers of cardiomyocytes within, but not outside, the infarct
BZ (Figure 6C). Importantly, no re-expression of SM-actinin
and Runx1 was observed in the infarcted area of Ob KO mice
after MI (Figures 6B and 6C), indicating that cardiomyocyte
dedifferentiation critically depends on OSM signaling under
both acute and chronic disease conditions.426 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier IncOSM Protects Heart Function after Acute Myocardial
Damage but Promotes Functional Deterioration
and Lethality When Chronically Activated in DCM
To study the effects of OSM inhibition and the resulting block
of cardiomyocyte dedifferentiation after acute cardiac damage,
we induced MI by LAD ligation at a distal position. In WT
mice, the distal LAD occlusion affected ejection fraction, cardiac.
Figure 5. Deletion of Ob Abrogates Expression of Fetal Gene Markers and Cardiomyocyte Remodeling in MCP-1 Transgenic Mice
(A and B) Western blot and (C) immunofluorescence analysis of the myocardium of 6-month-old MCP-1 transgenic (MCP-1), WT control (WT), andMCP-1/Ob/
(MCP-1/KO) mice. (A) Increased expression of Ob and OSM, but not of LIF, in the myocardium of MCP-1 animals in comparison to age-matched WT controls.
(B) Inactivation of Ob reduces expression of B-Raf, ANP, Dab2, and Runx1 in MCP-1 transgenic mice. Error bars represent standard errors. (C) Deletion of OSM
receptor leads to reduced expression of SM-actinin (green) and ANP (green) expression in cardiomyocytes (red) of MCP-1 animals. See also Figure S4.
Cell Stem Cell
OSM and Cardiomyocyte Dedifferentiationoutput, and left ventricle (LV) chamber volume only to a minor
extent (Figure S5A). Deletion of Ob, which abrogates OSM
signaling, however, resulted in a significant decline of left ventric-
ular function. The ejection fraction dropped from 40.9% ± 1.4%
inWT animals to 31.7% ± 1.7% (p < 0.001; n = 9 per group) in the
KO group. The cardiac output went down from 14.5 ± 0.6 to
12.4 ± 0.7 ml/min (p < 0.05; n = 9 per group) and the end-systolic
volume increased from45.6 ± 2.6 ml to 65.2 ± 4.1ml (p < 0.05; n = 9
per group) (Figure S5A). In addition, we observed a major
increase in postinfarction lethality in Ob-deficient mice as
compared with the WT group (Figure 6D). Viability of KO mice
was down to only 44.8% (13 of 29) compared with 81.5% (22Celof 27) in WT mice 4 weeks after the operation (Figure 6D).
Conversely, we observed a major improvement of cardiac func-
tion and survival when animals subjected to proximal LAD liga-
tion were treated daily with 250 ng OSM per gram of body weight
7 days before and 7 days after MI. Viability of OSM-treated mice
was up to 93% (14 of 15) as compared with 59% (16 of 27) in
untreated mice 4 weeks after the operation (Figure 6E). The
improved survival rate was accompanied by better cardiac func-
tion (Movie S2). Ejection fraction increased from 18.1%±4.9% in
untreated animals to 27.3%± 9.2% (p < 0.02; n = 10 per group) in
the OSM-treated group. The cardiac output went up from 14.2 ±
1.7 to 19.9 ± 3.6 ml/min (p < 0.05; n = 10 per group) and the end-l Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Inc. 427
Figure 6. Deletion of Ob Abrogates Cardiomyo-
cyte Dedifferentiation in the Border Zone after
Myocardial Infarction
(A–C) Immunofluorescence analysis of the infarct area and
the border zone of 3-month-old Ob KO (KO) and WT
mice 3 weeks after acute myocardial infarction (MI). (A)
The infarct area and the neighboring infarct border zone
are infiltrated with macrophages expressing OSM. (B)
SM-actinin (green) is expressed in border zone cardio-
myocytes (marked by F-actin staining in red) ofWT, but not
Ob KO, mice (scale bars: 30 mm). (C) Runx1 (red) is ex-
pressed in nuclei of cardiomyocytes (green) in the border
zone of WT, but not Ob KO, mice (scale bars: 40 mm).
(D) Kaplan-Meier survival curve demonstrating that dele-
tion of Ob increases lethality after acute MI.
(E) Kaplan-Meier survival curve demonstrating that treat-
ment with OSM improves survival in mice after acute MI.
p values and animal number are shown. Please note that
LAD ligations in (D)were done at amore distal position than
those of (E) to generate smaller infarcts.
See also Figure S5 and Movie S2.
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OSM and Cardiomyocyte Dedifferentiationsystolic volume decreased from 162.1 ± 53.0 ml to 90.1 ± 50.1ml
(p < 0.01; n = 10 per group) (Figure S5B).
We next investigated whether the block of cardiomyocyte
dedifferentation and the major improvements of biochemical
and morphological parameters in MCP-1/Ob/ mice rescued
LV functions in our DCM model. To our surprise inactivation of
Ob in MCP-1 mice resulted in a virtually complete normalization
of all functional cardiac parameters at 6 months. No significant
decline of ejection fraction was monitored when Ob//MCP-1
mice were compared to WT mice (ejection fraction: 49.2% ±
0.8% in Ob//MCP-1 versus 55.4% ± 3.4% in WT). Similarly,
fractional shortening (36.8% ± 3% versus 37.5% ± 1.8%),
cardiac output (17.3 ± 0.3 ml/min versus 17.1 ± 0.4 ml/min),
and end-systolic volume (37.5 ± 0.3 ml versus 36.9 ± 2.8 ml)
showednormal valueswhileOb+/+/MCP-1micedisplayed severe
signs of cardiac failure, including LV dilation (Figure 7A). More-
over, inactivation of OSM signaling resulted in a sig-
nificant extension of the lifespan of MCP-1 mice. Only very few
Ob//MCP-1 mice died, whereas the majority of Ob+/+/MCP-1
mice died within the 36 weeks of observation (Figure 7B).428 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier Inc.We conclude that OSM signaling exerts
protective effects during acute MI, probably
through partial dedifferentiation of cardiomyo-
cytes. Apparently, it is vital to limit the extent
of dedifferentiation and remodeling of cardio-
myocytes, because excessive OSM signaling,
which occurs in chronic disease conditions
such as DCM, will contribute to the decline of
contractile force and favor adverse cardiac
remodeling.
DISCUSSION
Here, we demonstrate that OSM is a major
modulator of cardiac remodeling and heart
failure that induces dedifferentiation of cardio-
myocytes and expedites loss of contractility.
We discovered that OSM-mediated cardiomyo-cyte dedifferentiation protects the heart after acute myocardial
damage but promotes functional deterioration and lethality
upon chronic activation in DCM. Our findings identify OSM as
a key modulator for progression of heart failure in DCM. We
reason that differences in the expression level of OSM, which
might depend on the degree of infiltration of affected hearts
with macrophages, different kinetics of OSM release, or differen-
tial responses to Ob signaling, might contribute to the diverse
clinical picture of dilated cardiomyopathy. Conversely, the
protective effects exerted by OSM signaling after cardiac infarc-
tion probably via induction of cardiomyocyte dedifferentiation
might have an important role in containing the extent of myocar-
dial tissue damage.
Many features of cardiomyocytes found in diseased hearts
in patient samples and in animal models associated with
increased OSM concentrations in vivo, such as dedifferentiation
and remodeling, were also observed in OSM-stimulated cell
cultures, offering the opportunity for us to study involved
signaling pathways in more detail. For example, loss of preexist-
ing sarcomeric structures and activation of fetal gene markers
Figure 7. Improvement of Cardiac Function in
MCP-1 Transgenic Animals by Inactivation of Ob
Allele
(A) End-systolic (Sys)/End-diastolic (Dia) midventricular
MRI short-axis frames of WT, OSM-receptor-KO (KO),
MCP-1, and MCP-1/KO 6-month-old mice. Homozygous
loss of OSM receptor in MCP-1mice resulted in significant
preservation of left ventricular geometry with reduced
ventricular dilatation and improvement of LV function.
Improvement was significant in all functional parameters.
Error bars represent standard errors.
(B) The Kaplan-Meier survival curve reveals significant
reduced survival of MCP-1/KO compared with MCP-1
mice (significance and animal number are shown in the
graphs).
(C) Model depicting the function of OSM during acute and
chronic injury of the myocardium. Initial injury (i.e., MI)
leads to invasion of macrophages, which release OSM.
Activation of Ob initially protects cardiomyocytes by
initiation of dedifferentiation and remodeling. Continuous
OSM signaling impairs cardiac function, eventually re-
sulting in heart failure.
See also Figure S5 and Movie S2.
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perfectly to activation of fetal gene markers and suppression of
the postnatal gene program in the failing heart (Taegtmeyer
et al., 2010). The in vitro analysis revealed that these processes
were mainly initiated by OSM because a wide spectrum of other
cardioactive proteins such as TNFa, MCP-1, and other members
of the IL-6 class of cytokines evoked only minor responses.
Further biochemical experiments revealed that the intracellular
effects of OSM are mainly mediated by the Ras/Raf/MEK/Erk
cascade, which is linked to activation of the Ob/gp130 receptor
by JAK-dependent phosphorylation of the docking site for SHP-
2 (Heinrich et al., 2003).
We postulate that OSM promotes loss of cardiac contractility
via two different routes. (1) It induces an irregular arrangement
of various types of contractile proteins. (2) It induces a major
reduction of the amount of myofilaments, which results in an
almost complete loss of cross-striations in OSM-treated cul-
tures. In our experiments short-term injections of OSM intoCell Stem Cell 9, 420mice induced a major rearrangement of the
cytoskeleton as indicated by re-expression of
a-SM-actin and actin dynamizing proteins
such as destrin, which reflect several features
of cardiomyocytes in failing hearts, in particular
disorganization of cytoskeletal filaments (Heling
et al., 2000; Schaper et al., 1991). We did not,
however, detect major dedifferentiation of car-
diomyocytes in vivo after short-term administra-
tion of OSM, whereas treatment of cultured
adult cardiomyocytes led both to dramatic
loss of sarcomeric structures and rearrange-
ment of the cytoskeleton. The difference might
be due to the complete mechanical unloading
of cultured cardiomyocytes and the extended
OSM treatment that was possible in vitro.
Our finding that OSM-mediated induction of
cardiomyocyte dedifferentiation helped tomaintain cardiac performance and decreased mortality after
cardiac infarction clearly demonstrated the beneficial role of
timely and locally restricted cardiomyocyte dedifferentiation. It
seems reasonable to assume that OSM-induced dedifferentia-
tion of cardiomyocytes causes a transient increase of resistance
to hypoxia. In fact, dedifferentiation and loss of contractile mate-
rial have been reported in hibernating myocardium and in infarct
BZs, leading to the conclusion that dedifferentiated cardiomyo-
cytes are more ischemia tolerant (Ausma et al., 1998; Dispersyn
et al., 2002; Taegtmeyer et al., 2010).
The expression of typical progenitor cell markers such as c-kit,
Runx1, and Dab2 in OSM-treated cardiomyocytes, and also
in vivo in the BZ of infarcted hearts, raises the intriguing possi-
bility that OSM induces a state in cardiomyocytes that is close
to that of cardiac progenitor cells. In particular the expression
of Runx1 and c-kit in cardiomyocytes exposed to OSM is inter-
esting because Runx1 has been defined as the master transcrip-
tion factor that controls the emergence of blood stem cells–432, November 4, 2011 ª2011 Elsevier Inc. 429
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OSM and Cardiomyocyte Dedifferentiation(Dzierzak and Speck, 2008) and also sets up proper develop-
ment and long-term function of adult hair follicle stem cells
(Osorio et al., 2011). c-kit on the other hand is a widely used
marker for endogenous cardiac progenitor cells (Beltrami et al.,
2003), although the biological functions of c-kit-positive cardiac
progenitor cells are still a matter of debate (Braun and Martire,
2007). The hypothesis that OSM—at least partially—induces
a cardiac-progenitor-like state is also supported by our finding
that OSM-treated cardiomyocytes show an improved ability to
enter the cell cycle. Yet, we want to make clear that we do not
claim that OSM treatment alone is sufficient to induce bona
fide cardiac progenitors, thought it does facilitate acquisition of
properties of progenitor cells in cardiomyocytes.
While theprecisemechanismbywhichOSMsignaling protects
the myocardium is unclear, our findings about the biological
effects of OSM in cultured cardiomyocytes and the myocardium
provide a number of clues: (1) one of the most striking effects of
OSM on cultured cardiomyocytes is a marked increase in size.
It is tempting to speculate that an increase in size enables
surviving myocytes in the damaged myocardium to reestablish
cellular contacts, a process that is well known to increase cellular
survival (Ruoslahti, 1997). (2) In cell culture assays we found that
OSM-treated cardiomyocytes are more resistant to episodes of
hypoxia, whereas knockdownofObby siRNA reversed this effect
(T.K., unpublished data). We also know from previous in vitro
experiments that dedifferentiation of cardiomyocytes coincides
with increased stress resistance and cell survival (Kubin et al.,
1999). The view that dedifferentiation of cardiomyocytes and
activation of fetal genes is an adaptive process associated with
survival rather than deterioration of cardiac function has gained
more acceptance in recent years, moving away from the tradi-
tional view that activation of fetal genes is an adverse response
of the myocardium (Taegtmeyer et al., 2010).
The initial benefit of cardiomyocyte dedifferentiation in
situations of acute myocardial damages will turn into a major
burden in chronic disease conditions with permanent expo-
sure of cardiomyocytes to OSM signaling (Figure 7C). Extensive
and lasting dedifferentiation of cardiomyocytes, as for example
during chronic DCM, will lead to a reduction of contractile force,
favoring ventricular dilation in particular in combination with
increased hemodynamic load. This phenomenon might also
explain why evolution has selected against a widespread
activation of dedifferentiation/redifferentiation-based regenera-
tive pathways in mammals. Such pathways can probably only
be fully activated in organisms such as zebrafish and newts,
which do not need to cope with the workload required to
maintain high blood pressure (Laube et al., 2006). Mammals
might have acquired signaling pathways that inhibit complete
dedifferentiation. Manipulation of such pathways might enable
comprehensive deprogramming of cardiomyocytes, leading to
the generation of proliferating cardiac progenitor cells in situ.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
UO126 and antibodies directed against phospho-Erk1/2, pan-actin, and TGF-
bR1 were from Cell Signaling Technology. Antibodies recognizing Ral A,
B-Raf, Erk1/2, Dab2, and phospho-gp130 were from Becton Dickinson. Anti-
bodies against troponin, destrin, SM-actin, and sarcomeric and pan a-actinin
were from Sigma. Rabbit monoclonal antibodies recognizing SM-actinin,430 Cell Stem Cell 9, 420–432, November 4, 2011 ª2011 Elsevier IncRunx1, and sarcomeric a-actinin were from Epitomics. Antibodies recognizing
Ob were purchased from ProteinTech Group and R&D systems. Antibodies
against ANP (precursor) were from Chemicon and R&D systems. Antibodies
recognizing OSM and LIF were from R&D systems. All recombinant
mouse proteins were from Cell Concepts with the exception of mouse OSM
and mouse LIF, which were obtained from Sigma and R&D systems.
OSM receptor beta siRNA (ON-TARGETplusSMARTpool L-087727-01-0010,
NM_001005384), Erk1 (L-100592-01, NM_017347), and Erk2 (L-096054-01,
NM_053842) were obtained from Dharmacon together with the corresponding
transfection kits.Treatment of Transgenic Animals and Cardiomyocyte Cultures
The generation of MCP-1 transgenic mice (Kolattukudy et al., 1998) and of
OSM receptor KO mice have been described previously (Tanaka et al.,
2003). To analyze the effect of OSM on the myocardium, 6-month-old FVB
mice were injected intraperitoneally twice daily with 60 ng OSM per gram of
body weight for 14 days. Ventricular cardiac myocytes of adult rats were
isolated and plated at a density of 1.5 3 104 cells/cm2 on laminin-coated
(10 mg/ml; Sigma) chamber slides as described previously (Kubin et al.,
1999). For cytokine exposure experiments myocytes were allowed to recover
for the first 2 days in 2% fetal calf serum (FCS) andwere then kept serum-free if
not indicated otherwise. Thereafter, basic medium, FCS, 50 ng/ml IGF-1, or
20 ng/ml of cytokines were added as indicated. Media were replaced every
other day. Five micomolar UO126 was added to the cultures 1 hr prior to stim-
ulation. Transfection of cardiomyocytes was performed using 0.5 mM siRNA
per culture according to the instructions of the manufacturer (Dharmacon).Ligation of LAD and Magnetic Resonance Imaging
Male Ob-KO mice (KO) and C57Bl/6 WT mice at 3 months of age (25–30 g)
were subjected to permanent ligation of the LAD as described previously (Ebelt
et al., 2007). Ligations were either performed at a proximal (1–2 mm lower than
the tip of the left auricle) or a distal localization (distal to the diagonal branch).
Cardiac magnetic resonance imaging was performed as described previously
(Ziebart et al., 2008).Human Heart Tissue
Hearts were obtained from patients at the time of transplantation surgery. Nine
patients suffering from end-stage heart failure (ejection fraction%23%) (Heling
et al., 2000) due to DCMwere studied. Four hearts from donors with normal left
ventricular function not used for transplantation served as controls. The study
was approved by the institutional ethical committee following standard
procedures.Protein Extracts, Western Blots, Morphological Analysis, and Real
Time Quantitative RT-PCR
Tissue samples were prepared following standard procedures. Immunoreac-
tive proteins were visualized on the VersaDoc (BioRad) and analyzed using
the QuantityOne software (BioRad). Samples were processed for immuno-
cytochemistry and fluorescence microscopy as previously described (Kubin
et al., 1999). Quantitative RT-PCR was done using the iCycler (Biorad) as
described (Neuhaus et al., 2003).Statistics
For statistical analysis the following tests (two-tailed) were used: (1) three or
more groups: 1 factorial ANOVA and subsequent Bonferroni multiple compar-
isons or Kruskal-Wallis test and subsequent Dunn’s multiple comparisons in
the case of missing normality and/or heterogeneous variance of the data. (2)
Two groups: unpaired t test or Mann-Whitney U test in the case of missing
normality and/or heterogeneous variance of the data. p < 0.05 was considered
statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes two tables and five figures
and can be found with this article online at doi:10.1016/j.stem.2011.08.013..
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